首页> 外文期刊>Antimicrobial agents and chemotherapy. >In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
【24h】

In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

机译:β-内酰胺酶抑制剂克拉维酸,舒巴坦和他唑巴坦单独或与β-内酰胺结合使用对流行病学上表征的多重耐药鲍曼不动杆菌菌株的体外活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Acinetobacter baumannii is an important nosocomial pathogen usually in the context of serious underlying disease. Multidrug resistance in these organisms is frequent. The beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam have intrinsic activity against Acinetobacter strains. To evaluate their potential therapeutic usefulness, we determined the in vitro activity of ampicillin, sulbactam, ampicillin-sulbactam, cefoperazone, cefoperazone-sulbactam, piperacillin, piperacillin-sulbactam, tazobactam, piperacillin-tazobactam, amoxicillin, clavulanic acid, amoxicillin-clavulanic acid, ticarcillin, and ticarcillin-clavulanic acid against multidrug-resistant A. baumannii. All isolates were epidemiologically characterized by RAPD [random(ly) amplified polymorphic DNA] analysis and/or pulsed-field gel electrophoresis and represented different strain types, including sporadic strains, as well as outbreak-related strains. The MICs were determined by agar dilution on Mueller-Hinton agar (using fixed concentrations, as well as fixed ratios for beta-lactamase inhibitors) and the E-test. The majority of E-test results were within two dilutions of those recorded by agar dilution, with the exception of piperacillin-tazobactam. Sulbactam was superior to clavulanic acid and tazobactam and may represent an alternative treatment option for infections due to multiresistant A. baumannii strains. beta-Lactamase inhibitors have intrinsic activity but do not enhance activity of beta-lactams against A. baumannii. Testing with the inhibitor added at a fixed concentration as recommended for piperacillin-tazobactam and ticarcillin-clavulanic acid by the National Committee for Clinical Laboratory Standards may falsely suggest high activity or gives uninterpretable results due to trailing. If combinations are used for testing, fixed ratios may give more useful results.
机译:鲍曼不动杆菌通常是重要的基础疾病,是重要的医院病原体。在这些生物中,多药耐药性很常见。 β-内酰胺酶抑制剂棒酸,舒巴坦和他唑巴坦具有针对不动杆菌菌株的固有活性。为了评估其潜在的治疗作用,我们确定了氨苄西林,舒巴坦,氨苄西林-舒巴坦,头孢哌酮,头孢哌酮-舒巴坦,哌拉西林,哌拉西林-舒巴坦,他唑巴坦,哌拉西林-他唑巴坦,阿莫西林,克拉维酸,阿维西林替卡西林和替卡西林-克拉维酸对多重耐药的鲍曼不动杆菌。所有分离株均通过RAPD [随机扩增多态性DNA]分析和/或脉冲场凝胶电泳进行流行病学鉴定,并代表不同的菌株类型,包括散发菌株以及与暴发相关的菌株。 MIC是通过在Mueller-Hinton琼脂上进行琼脂稀释(使用固定的浓度以及β-内酰胺酶抑制剂的固定比例)和E测试确定的。除哌拉西林-他唑巴坦外,大多数E-检验结果均在琼脂稀释记录的两个稀释度之内。舒巴坦优于克拉维酸和他唑巴坦,可能代表多重耐药鲍曼不动杆菌引起的感染的另一种治疗选择。 β-内酰胺酶抑制剂具有内在活性,但不增强β-内酰胺类对鲍曼不动杆菌的活性。国家临床实验室标准委员会建议以固定浓度添加的抑制剂对哌拉西林-他唑巴坦和替卡西林-克拉维酸推荐的检测方法可能会错误地提示其具有高活性或由于拖尾而产生无法解释的结果。如果将组合用于测试,则固定比率可能会提供更有用的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号